Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 data in H2 2026. Read the full analysis here.

Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage ...

Biomarkers associated with cognitive impairment differ between men and women with chronic kidney disease, according to data ...

2025 has proved to be a turnaround for the German pharmaceutical giant Bayer BAYRY. Shares have skyrocketed 121.6% over the past year compared with the industry’s gain of 19.2%. The stock has also ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ...

The study analyzed more than 100 million U.S. medical claims from July 1, 2022, through June 30, 2024, and found that nearly one in three eligible heart failure patients are not being treated with ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

The American College of Cardiology issued its inaugural JACC Cardiovascular Statistics report, highlighting the prevalence of ...

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...

A structured, tiered catalogue of standards for heart failure outcome measures has been developed via a major international ...

Most of what people casually call “the universe” is not where instinct suggests. Stars, planets and glowing gas clouds are ...